Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

POAI Predictive Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: POAI

Price (delayed)

$0.9575

Market cap

$8.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.74

Enterprise value

$7.38M

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data ...

Highlights
The EPS has soared by 52% YoY and by 25% from the previous quarter
The company's debt fell by 26% YoY and by 9% QoQ
Predictive Oncology's equity has shrunk by 104% YoY but it has increased by 28% QoQ
Predictive Oncology's quick ratio has decreased by 46% YoY
POAI's gross profit is down by 32% year-on-year and by 17% since the previous quarter
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.precisiontherapeutics.com
Peers: OFIX

Key stats

What are the main financial stats of POAI
Market
Shares outstanding
8.93M
Market cap
$8.55M
Enterprise value
$7.38M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
5.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.48
Earnings
Revenue
$1.35M
Gross profit
$660,672
Operating income
-$9.93M
Net income
-$10.89M
EBIT
-$10.89M
EBITDA
-$10.19M
Free cash flow
-$9.3M
Per share
EPS
-$1.74
EPS diluted
-$1.74
Free cash flow per share
-$1.3
Book value per share
-$0.02
Revenue per share
$0.19
TBVPS
$0.81
Balance sheet
Total assets
$5.87M
Total liabilities
$6.01M
Debt
$1.92M
Equity
-$145,796
Working capital
-$1.12M
Liquidity
Debt to equity
-13.16
Current ratio
0.76
Quick ratio
0.68
Net debt/EBITDA
0.11
Margins
EBITDA margin
-756.8%
Gross margin
49.1%
Net margin
-808.8%
Operating margin
-737.2%
Efficiency
Return on assets
-150.6%
Return on equity
-762.4%
Return on invested capital
-498%
Return on capital employed
-864.7%
Return on sales
-808.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

POAI stock price

How has the Predictive Oncology stock price performed over time
Intraday
-3.38%
1 week
5.8%
1 month
-12.95%
1 year
-34.42%
YTD
16.77%
QTD
-37.01%

Financial performance

How have Predictive Oncology's revenue and profit performed over time
Revenue
$1.35M
Gross profit
$660,672
Operating income
-$9.93M
Net income
-$10.89M
Gross margin
49.1%
Net margin
-808.8%
POAI's gross profit is down by 32% year-on-year and by 17% since the previous quarter
POAI's operating income is up by 26% YoY and by 9% QoQ
POAI's net income is up by 26% year-on-year and by 14% since the previous quarter
Predictive Oncology's gross margin has decreased by 24% YoY

Price vs fundamentals

How does POAI's price correlate with its fundamentals

Growth

What is Predictive Oncology's growth rate over time

Valuation

What is Predictive Oncology stock price valuation
P/E
N/A
P/B
N/A
P/S
5.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.48
The EPS has soared by 52% YoY and by 25% from the previous quarter
Predictive Oncology's equity has shrunk by 104% YoY but it has increased by 28% QoQ
The P/S is 74% lower than the 5-year quarterly average of 19.4
POAI's revenue is down by 17% from the previous quarter and by 10% YoY

Efficiency

How efficient is Predictive Oncology business performance
The return on assets has dropped by 63% year-on-year
The company's return on equity fell by 49% QoQ
Predictive Oncology's ROIC has decreased by 48% YoY and by 18% from the previous quarter
The ROS has increased by 18% YoY but it has decreased by 3.7% from the previous quarter

Dividends

What is POAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for POAI.

Financial health

How did Predictive Oncology financials performed over time
The company's total assets is 2.4% lower than its total liabilities
The current ratio has declined by 48% year-on-year but it has increased by 23% since the previous quarter
Predictive Oncology's quick ratio has decreased by 46% YoY
Predictive Oncology's equity has shrunk by 104% YoY but it has increased by 28% QoQ
The debt to equity has contracted by 26% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.